Brokerages Set Simulations Plus, Inc. (NASDAQ:SLP) Target Price at $24.40

Simulations Plus, Inc. (NASDAQ:SLPGet Free Report) has received an average rating of “Hold” from the eleven ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $24.40.

A number of equities analysts have weighed in on SLP shares. Cowen began coverage on Simulations Plus in a research report on Tuesday, September 30th. They set a “hold” rating for the company. Citigroup restated a “market perform” rating on shares of Simulations Plus in a report on Tuesday, October 28th. BTIG Research lowered shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research note on Thursday, December 18th. KeyCorp reissued a “sector weight” rating on shares of Simulations Plus in a research report on Wednesday, October 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Simulations Plus in a report on Wednesday, October 8th.

Get Our Latest Analysis on Simulations Plus

Institutional Investors Weigh In On Simulations Plus

A number of institutional investors and hedge funds have recently made changes to their positions in SLP. Wellington Management Group LLP acquired a new stake in shares of Simulations Plus during the 1st quarter worth about $2,458,000. Charles Schwab Investment Management Inc. raised its holdings in Simulations Plus by 16.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 166,392 shares of the technology company’s stock valued at $4,080,000 after acquiring an additional 23,139 shares during the period. Comerica Bank raised its holdings in Simulations Plus by 16.6% in the 1st quarter. Comerica Bank now owns 193,990 shares of the technology company’s stock valued at $4,757,000 after acquiring an additional 27,579 shares during the period. Versor Investments LP acquired a new stake in Simulations Plus during the second quarter worth approximately $496,000. Finally, Kopion Asset Management LLC lifted its position in Simulations Plus by 22.7% during the second quarter. Kopion Asset Management LLC now owns 156,401 shares of the technology company’s stock worth $2,729,000 after acquiring an additional 28,980 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Trading Down 2.2%

SLP stock opened at $18.76 on Tuesday. The stock has a 50-day moving average price of $18.00 and a two-hundred day moving average price of $16.27. Simulations Plus has a 1 year low of $12.39 and a 1 year high of $37.67. The stock has a market cap of $378.01 million, a PE ratio of -5.83 and a beta of 1.16.

Simulations Plus (NASDAQ:SLPGet Free Report) last issued its quarterly earnings results on Monday, December 1st. The technology company reported $0.10 EPS for the quarter, meeting analysts’ consensus estimates of $0.10. The company had revenue of $17.46 million for the quarter, compared to analyst estimates of $17.41 million. Simulations Plus had a positive return on equity of 13.27% and a negative net margin of 81.74%.During the same period in the previous year, the company posted $0.06 earnings per share. On average, analysts forecast that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

About Simulations Plus

(Get Free Report)

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.

Featured Stories

Analyst Recommendations for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.